netFormulary NHS
Isle of Wight
Formulary
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Section
Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
Drugs for cytotoxic-induced side-effects (2,0)
08.01.01 Alkylating drugs (6,0)
08.01.02 Anthracyclines and other cytotoxic antibiotics (6,0)
08.01.03 Antimetabolites (10,0)
08.01.04 Vinca alkaloids and etoposide (4,0)
08.01.05 Other antineoplastic drugs (16,0)
Bevacizumab (1,0)
Bortezomib (1,0)
Brentuximab vedotin (1,0)
Cetuximab (1,0)
Dacarbazine and Temozolomide (1,0)
Hydroxycarbamide (2,0)
Imatinab (0,0)
Panitumumab (0,0)
Platinum compounds (3,0)
Protein kinase inhibitors (9,0)
Taxanes (3,0)
Topoisomerase I inhibitors (2,0)
Trabectedin (1,0)
Trastuzumab (2,0)
Immunosuppressant therapy (0,0)
08.02.03 Anti-lymphocyte monoclonal antibodies (1,0)
08.02.04 Other immunomodulating drugs (6,0)
Interferon Alfa (1,0)
Interferon beta (1,0)
Interferon gamma (0,0)
BCG bladder instillation (0,0)
Canakinumab (0,0)
Dimethyl fumarate (0,0)
Fingolimod (0,0)
Histamine (0,0)
Lenalidomide, pomalidomide, and thalidomide (0,0)
Teriflunomide (0,0)
08.03 Sex hormones and hormone antagonists in malignant disease (0,0)
08.03.01 Oestrogens (1,0)
08.03.02 Progestogens (1,0)
08.03.03 Androgens (0,0)
08.03.04 Hormone antagonists (0,0)
08.03.04.01 Breast cancer (6,0)
Gonadorelin analogues (1,0)
Anti-androgens (8,0)
08.03.04.03 Somatostatin analogues (4,0)
netFormulary